得力生注射液联合TP方案治疗非小细胞肺癌的临床获益分析  

The clinical efficacy of DeLiSheng injection combined with TP regimen for advanced non-small cell lung cancer

作　　者：王旸[1] 万里新[1] 

机构地区：[1]南阳市中心医院放疗科,473009

出　　处：《中国实用医药》2008年第21期63-64,共2页China Practical Medicine

摘　　要：目的观察得力生注射液配合TP方案治疗中晚期非小细胞肺癌(NSCLC)的临床综合获益。方法联合组50例患者接受得力生注射液配合TP方案治疗,对照组48例单用TP方案;两组均以21d为1个周期,重复3个周期。结果联合组和对照组的有效率分别为52%和45.8%,两组差异无统计学意义(P>0.05);生活质量改善率分别为84%和%52.1%,两组差异有统计学意义(P<0.05);联合组主要毒副作用发生率低于对照组,差异有统计学意义(P<0.05)。结论得力生注射液联合TP方案对进展非小细胞肺癌有效,对临床症状的改善,提高生存质量和减轻毒副作用均有较好的作用。Objective To observe the efficacy and side effect of Delisheng injection combined with TP regimen in the treatment of advanced non-small cell lung cancer（NSCLC）. Methods Combined group including 50 patients were treated with DeLiSheng injection combined TP regimen, control group including 48 patients were treated by TP regimen, cycles were repeated 3 weeks. Results in the combined group effective rate is 52%. in the control group effective rate is 45.8%. significant difference was not observed between the two groups（ P 〉 0. 05 ）. For the side effect and life quality, significant differences were observed between the two groups（P 〈 0. 05 ）. Conclusion The combination of Delisheng injection and TP regimen is feasible and well tolerated should be taken as an energetic scheme for advanced non-small lung cancer.

关 键 词：得力生注射液 TP方案 非小细胞肺癌 

分 类 号：R734.2[医药卫生—肿瘤] R735.05[医药卫生—临床医学]